Abstract PS7-59: Presence of comorbidities and use of concomitant medications associated with QTC prolongation/torsades de pointes in patients with HR+/HER2- advanced breast cancer

尖端扭转 医学 QT间期 相伴的 内科学 心肌梗塞 乳腺癌 长QT综合征 心脏病学 癌症 共病 人口 心力衰竭 环境卫生
作者
Reshma Mahtani,Katie Lewis,Emily Clayton,Matthew Last,Debanjali Mitra,Samantha Kurosky
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:81 (4_Supplement): PS7-59
标识
DOI:10.1158/1538-7445.sabcs20-ps7-59
摘要

Abstract BACKGROUND: Corrected QT (QTc) prolongation is a cardiac condition that may increase the risk of ventricular arrhythmias, including Torsades de Pointes (TdP), and cardiac-related death. QTc prolongation is a notable concern in oncology as drug-induced QTc prolongation is a documented side effect of several anticancer therapies. Moreover, patient-specific risk factors for QTc prolongation such as increased age and a history of cardiovascular disease/events can be common among patients with metastatic breast cancer, which puts this population at an increased baseline risk for QTc prolongation. Female sex is a risk factor itself. The objective of this study was to characterize the presence of comorbidities and use of concomitant medications associated with QTc prolongation/TdP among patients receiving first-line (1L) treatment for HR+/HER2- locally advanced or metastatic breast cancer (aBC).METHODS: Oncologists in France, Germany, Israel, Italy, Spain and the United States abstracted clinical characteristics and medication data from the medical records of patients, aged ≥18, who received 1L treatment for HR+/HER2- aBC between 10/2019 and 02/2020. The presence of comorbidities (e.g., congestive heart failure, myocardial infarction, history of atrial arrythmias) and utilization of concomitant medications (excluding anti-cancer therapies) with known, possible, or conditional risk for QTc prolongation/TdP were summarized. The list of comorbidity risk factors was compiled from a targeted literature search and clinician review. The list of concomitant medications was obtained from crediblemeds.org.RESULTS: A total of 1164 patients with aBC were sampled across the six countries. Among them, 99% were female and the mean age was 62 years. The majority of patients had metastatic disease (85%); 15% had locally advanced disease. Among those with metastatic disease, 47% had visceral metastasis and 34% had bone-only metastasis. At 1L initiation, 84% of patients had an ECOG score of 0/1. Comorbidities associated with risk of QTc prolongation/TdP were observed in 8% of patients; the most frequently observed were congestive heart failure (3%) and history of myocardial infarction (2%) (Table 1). The proportion of patients who received at least one medication associated with risk of QTc prolongation/TdP was 39%. Overall, 42% of patients had at least one comorbidity or medication associated with risk of QTc prolongation/TdP. CONCLUSIONS: Approximately 2 out of 5 patients receiving 1L treatment for HR+/HER2- aBC had a comorbidity or utilized a concomitant medication that could increase risk of QTc prolongation/TdP. As cardiovascular toxicity is a known side effect associated with several anticancer therapies, the high prevalence of coexisting risk factors among patients receiving 1L treatment underscores the importance of assessing patients’ existing risk when selecting treatments for advanced breast cancer. Table 1. Presence of Comorbidities and Use of Concomitant Medications with known, possible, or conditional risk for QTc prolongation/TdP in Patients Who Received First-Line Therapy for HR+/HER2- Advanced Breast CancerN%Total Patients1164100ComorbiditiesMyocardial infarction202Congestive heart failure323Moderate or severe liver disease3<1History of QT prolongation3<1Bradyarrhythmia3<1History of atrial arrhythmias282History of ventricular arrhythmias1<1Hypo/hyperkalemia81Hypo/Hypercalcemia81Disorders of magnesium metabolism81Disorders of phosphorus metabolism2<1Unstable angina4<1Presence of comorbidity QTc risk factor948Mean (SD) number of conditions per patient1.3 (.4)Received medication considered a risk factor for QTc prolongation45039Presence of QTc risk factor condition or medication49042 Citation Format: Reshma Mahtani, Katie Lewis, Emily Clayton, Matthew Last, Debanjali Mitra, Samantha Kurosky. Presence of comorbidities and use of concomitant medications associated with QTC prolongation/torsades de pointes in patients with HR+/HER2- advanced breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-59.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
耳百完成签到,获得积分10
1秒前
3秒前
4秒前
5秒前
6秒前
6秒前
CR7应助越啊采纳,获得20
7秒前
李健应助123采纳,获得10
8秒前
Jun完成签到,获得积分10
9秒前
大反应釜发布了新的文献求助10
9秒前
淳于安筠发布了新的文献求助30
12秒前
柳叶洋完成签到,获得积分10
12秒前
下一秒发布了新的文献求助10
15秒前
16秒前
17秒前
无花果应助科研通管家采纳,获得10
17秒前
Akim应助科研通管家采纳,获得10
17秒前
852应助科研通管家采纳,获得10
17秒前
SYLH应助科研通管家采纳,获得30
17秒前
斯文败类应助科研通管家采纳,获得10
17秒前
Owen应助科研通管家采纳,获得10
17秒前
orixero应助科研通管家采纳,获得10
17秒前
Orange应助科研通管家采纳,获得10
17秒前
情怀应助科研通管家采纳,获得30
17秒前
Jasper应助科研通管家采纳,获得10
18秒前
英俊的铭应助科研通管家采纳,获得10
18秒前
18秒前
Ava应助科研通管家采纳,获得10
18秒前
情怀应助科研通管家采纳,获得10
18秒前
18秒前
18秒前
18秒前
18秒前
SYLH应助shensiang采纳,获得20
19秒前
专一的从波完成签到 ,获得积分10
19秒前
领导范儿应助msjs采纳,获得30
19秒前
量子星尘发布了新的文献求助10
21秒前
安静的幼旋完成签到,获得积分10
22秒前
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174